T3	duration 496 533	Between October 1995 and October 1999
T4	No-of-participants 535 538	426
T5	eligibility 539 604	postmenopausal women with hormone receptor-positive breast cancer
T6	outcome-Measure 650 671	efficacy and toxicity
T7	No-of-participants 673 698	Four hundred and nineteen
T8	outcome 842 862	DFS, TTR or survival
T9	outcome 878 895	stopped treatment
T10	outcome 953 973	Grade 3/4 toxicities
T11	adverse-effect 985 1000	visual problems
T12	adverse-effect 1005 1031	musculoskeletal complaints
T1	intervention 85 94	tamoxifen
T2	control 99 124	tamoxifen and fenretinide
